Ticker Details
Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals Inc is the RNA-targeted drug discovery and development company. Its broad pipeline consists of close to 32 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe, and rare diseases.
IPO Date:	December 22, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$9.93B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.99 | 2.12%
Avg Daily Range (30 D):	$1.18 | 2.07%
Avg Daily Range (90 D):	$1.20 | 1.76%

Institutional Daily Volume
Avg Daily Volume:	1.24M
Avg Daily Volume (30 D):	2.69M
Avg Daily Volume (90 D):	2.08M

Trade Size
Avg Trade Size (Sh.):	80
Avg Trade Size (Sh.) (30 D):	73
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	12,976
Avg Institutional Trade:	$3.04M
Avg Institutional Trade (30 D):	$4.02M
Avg Institutional Trade (90 D):	$4.95M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	4

Market Closing Trades
Avg Closing Trade:	$7.57M
Avg Closing Trade (30 D):	$26.75M
Avg Closing Trade (90 D):	$26.63M
Avg Closing Volume:	155.57K

News

Aug 22, 2026 @ 11:30 AM Breakfast News: A Conversation With Ionis CEO Source: Tmf Breakfast News

Aug 14, 2026 @ 10:15 AM Ionis Stock Has Plunged 30%. Is It Time to Buy the... Source: Rick Orford

Aug 3, 2026 @ 7:17 PM Ionis Pharmaceuticals Director Hayden Buys $1.1 Mi... Source: Brendan Coffey

Jul 28, 2026 @ 4:46 PM Ionis Pharmaceuticals, Inc. (IONS) Faces Investor ... Source: Hagens Berman

Jul 15, 2026 @ 8:10 AM Oligonucleotide CDMO Market to Reach USD 9.87 Bill... Source: Researchandmarkets.Com

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.47	$-.69	$-.56
Diluted EPS	$-.55	$-.69	$-.56
Revenue	$874.09M	$267.95M	$246.09M
Gross Profit	$858.07M	$265.21M	$243.11M
Net Income / Loss	$-565.17M	$-114.65M	$-92.53M
Operating Income / Loss	$-594.36M	$-102.29M	$-117.42M
Cost of Revenue	$16.02M	$2.74M	$2.98M
Net Cash Flow	$53.07M	$176.73M	$-198.74M
PE Ratio